1
|
· |
the initiation, cost, timing, progress and results of our current and future research and development activities, preclinical studies and clinical trials; |
|
· |
the potential benefits of strategic partnership agreements and our ability to enter into selective strategic partnership arrangements; |
|
· |
the timing of, and our ability to obtain and maintain, regulatory approvals for our product candidates; |
|
· |
our ability to quickly and efficiently identify and develop additional product candidates; |
|
· |
our ability to advance any product candidate into, and successfully complete clinical trials; |
|
· |
our intellectual property position, including with respect to our trade secrets; and |
|
· |
our estimates regarding expenses, future revenues, capital requirements, the sufficiency of our current and expected cash resources and our need for additional financing. |
2
|
· |
Linker stability: Linkers must be stable in the bloodstream to ensure that free payload is not released into circulation prior to delivery into the tumor. Free payload in circulation causes toxicity. Efforts to design better linkers to increase stability have, in turn, reduced the efficiency of payload release once the ADC is internalized in the tumor cell, resulting in decreased efficacy. |